Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For:	[Subscribe] [Scholar Register]

Number	Cited by Other Article(s)
1	Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis11T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis). Urol Oncol 2014;32:569-75. [DOI: 10.1016/j.urolonc.2013.12.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Revised: 12/02/2013] [Accepted: 12/17/2013] [Indexed: 11/23/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis11T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis). Urol Oncol 2014;32:569-75. [DOI: 10.1016/j.urolonc.2013.12.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Revised: 12/02/2013] [Accepted: 12/17/2013] [Indexed: 11/23/2022]